[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605062":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":36,"locations":46,"responsibleParty":65,"collaborators":67,"id":115,"slug":116,"hasResults":117,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":117,"sex":123,"minAge":124,"maxAge":25,"enrollmentInfo":125,"targetDuration":25,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":49,"whyStopped":25,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"tranexamic acid group","EXPERIMENTAL","In patients assigned to tranexamic acid, 2.0 g dissolved in 50 ml of 0.9% saline）will be given intravenously within 30 mins after skin incision.",[13],"Drug: tranexamic acid",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","PLACEBO_COMPARATOR","In patients assigned to placebo, a comparable volume of 0.9% saline will be given.",[19],"Drug: 0.9 % saline",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","tranexamic acid",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"0.9 % saline",[15],[30,34],{"name":31,"affiliation":32,"role":33},"liqun yang, MD, phD","Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":32,"role":33},"weifeng yu, MD, phD",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":25,"email":41},"xiaohua liu, MD, phD","CONTACT","+86 18116351197","xiaohualiu007@126.com",{"name":43,"role":39,"phone":44,"phoneExt":25,"email":45},"liqun yang, MD, PHD","+86 15921969001","lqyang72721@126.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Anesthesiology, Renji Hospital, Shanghai Jiao Tong university school of medicine.","RECRUITING","Shanghai","Shanghai Municipality","200123","China","CN",{"type":56,"coordinates":57},"Point",[58,59],121.45806,31.22222,{"lat":59,"lon":58},[62],{"name":63,"role":39,"phone":64,"phoneExt":25,"email":41},"xiaohua liu","+86 02168383702",{"type":66,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[68,70,72,74,76,78,80,82,84,86,88,90,92,94,96,98,100,102,104,106,108,110,112],{"name":69,"class":6},"West China Hospital",{"name":71,"class":6},"The Affiliated Hospital of Qingdao University",{"name":73,"class":6},"The First Affiliated Hospital of Zhengzhou University",{"name":75,"class":6},"Huashan Hospital",{"name":77,"class":6},"Tianjin First Central Hospital",{"name":79,"class":6},"The First Hospital of Jilin University",{"name":81,"class":6},"Third Affiliated Hospital, Sun Yat-Sen University",{"name":83,"class":6},"First Affiliated Hospital, Sun Yat-Sen University",{"name":85,"class":6},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"name":87,"class":6},"The First Affiliated Hospital with Nanjing Medical University",{"name":89,"class":6},"Tongji Hospital",{"name":91,"class":6},"People's Hospital of Guangxi Zhuang Autonomous Region",{"name":93,"class":6},"The First Affiliated Hospital of University of Science and Technology of China",{"name":95,"class":6},"The First Affiliated Hospital of Anhui Medical University",{"name":97,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":99,"class":6},"First Affiliated Hospital Xi'an Jiaotong University",{"name":101,"class":6},"Fujian Medical University Union Hospital",{"name":103,"class":6},"First Affiliated Hospital of Guangxi Medical University",{"name":105,"class":6},"Second Affiliated Hospital of Guangzhou Medical University",{"name":107,"class":6},"Zhejiang University",{"name":109,"class":6},"Hebei Medical University Third Hospital",{"name":111,"class":6},"Shandong First Medical University",{"name":113,"class":114},"Jinling Hospital, Medical School of Nanjing University","UNKNOWN","100605062","efficacy-and-safety-of-tranexamic-acid-in-adult-liver-transplantation---esta-trial-100605062",false,"NCT07157631","Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial","A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation (ESTA Trial)","ESTA","Inclusion Criteria:consenting adults aged at least 18 years who are scheduled for allogeneic liver transplantation with general anesthesia.\n\n\\-\n\nExclusion Criteria:1) History of arterial or venous thrombosis within 3 months; 2) Re-transplantation; 3) Known allergy to tranexamic acid; 4) Participation in potentially conflicting clinical trials; 5) Considered by the responsible surgeon or anesthesiologist to be unsuitable.\n\n\\-","ALL","18 Years",{"count":126,"type":127},1546,"ESTIMATED","INTERVENTIONAL",[130],"NA","We propose a multi-center randomized trial to test the primary hypothesis that tranexamic acid is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial 24 hours and that tranexamic acid is non-inferior to placebo for a composite of thrombotic events within the initial 7 postoperative days. Secondarily, we will determine whether tranexamic acid is superior to placebo on total postoperative drainage volume and blood product transfusion within the initial 3 postoperative days.\n\nWe propose to randomize patients to 2.0 g of tranexamic acid intravenously at the start of surgery or a comparable volume of 0.9% normal saline placebo. Because demonstrating safety will require more patients, our sample size is based on safety. Randomizing 1546 patients will provide 80% power for detecting a non-inferiority margin of 4% with a baseline incidence of 10% for composite thrombotic events within the initial 7 postoperative days.",[133,134,135],"Liver Transplantation","Tranexamic Acid","End-stage Liver Disease (ESLD)",[133,23],"2025-12-02",{"date":139,"type":140},"2025-12-08","ACTUAL",{"date":142,"type":140},"2025-11-01",{"date":144,"type":127},"2027-12-01",{"name":5,"class":6},1]